FAP: Not Just a Biomarker but Druggable Target in Liver Fibrosis
Cell Mol Gastroenterol Hepatol
.
2023;15(4):1018-1019.
doi: 10.1016/j.jcmgh.2022.12.018.
Epub 2023 Jan 18.
Authors
Jieun Kim
1
,
Ekihiro Seki
2
Affiliations
1
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
2
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: Ekihiro.Seki@cshs.org.
PMID:
36681094
PMCID:
PMC10040959
DOI:
10.1016/j.jcmgh.2022.12.018
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Comment
MeSH terms
Biomarkers
Humans
Liver Cirrhosis* / drug therapy
Serine Endopeptidases*
Substances
Serine Endopeptidases
Biomarkers
Grants and funding
R01 DK085252/DK/NIDDK NIH HHS/United States